Judith L. Swain's most recent trade in Lexicon Pharmaceuticals Inc was a trade of 103,806 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 103,806 | 103,806 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 89,312 | 89,312 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 36,810 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 36,810 | 85,174 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 44,906 | 44,906 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 36,810 | 36,810 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 48,364 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2024 | 8,032 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2023 | 9,302 | 40,332 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 12,658 | 12,658 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 8,032 | 8,032 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 14,402 | 14,402 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2022 | 9,302 | 9,302 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 31,030 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2022 | 4,024 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 6,475 | 6,475 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2021 | 4,024 | 4,024 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 27,006 (0%) | 0% | 0 | Common Stock | |
| Lexicon Pharmaceuticals Inc | Judith L. Swain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2021 | 10,638 | 0 | - | - | Restricted Stock Units |